Biohit Oyj

Biohit Oyj maintains a strong liquidity position with a current ratio of 2.56 and cash and equivalents of EUR 3.54 million, which supports its operational flexibility. The company's price-to-book ratio of 2.08 and price-to-tangible-book ratio of 2.08 indicate that the market values the company at a premium to its book value, suggesting confidence in its intangible assets and future earnings potential. In terms of profitability, Biohit Oyj reports a return on equity (ROE) of 18.33% and a return on assets (ROA) of 13.83%, both of which exceed the typical thresholds for the pharmaceutical industry. The company's operating income of EUR 2.92 million and net income of EUR 2.74 million reflect a healthy margin structure, although the gross profit margin of 68.3% is in line with industry norms. The company's revenue is concentrated in its Diagnostics segment, which is its sole business segment. Geographically, Biohit Oyj operates primarily in Europe and Asia, with no disclosed revenue breakdown by region. This concentration may expose the company to regional economic or regulatory risks, though the absence of immediate liquidity or dilution flags suggests a stable capital structure. Looking ahead, the company's revenue is expected to grow, supported by its strong cash flow generation and a free cash flow of EUR 2.54 million. The price target of EUR 3.50 from analysts implies a potential upside of 37.8% from the current market price of EUR 2.54, indicating positive sentiment about the company's future performance. The risk assessment for Biohit Oyj is favorable, with low liquidity and dilution risks. The company's debt-to-equity ratio of 0.11 and long-term debt of EUR 1.59 million suggest a conservative capital structure. No immediate filing-based liquidity or dilution flags were detected, and the company has not issued any recent equity, reducing the risk of dilution. Recent events, including the latest financial filings and analyst reports, show consistent performance and positive analyst sentiment. The mean recommendation of 2.00 (Buy) and the absence of strong-buy ratings indicate a cautious but optimistic outlook from the investment community.